Daniel Polhamus Selected Research

Dipeptidyl-Peptidase IV Inhibitors

3/2013

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Polhamus Research Topics

Disease

3	Breast Neoplasms (Breast Cancer) 01/2019 - 12/2017
1	Crohn Disease (Crohn's Disease) 03/2024
1	Ulcerative Colitis 03/2024
1	Giant Cell Tumor of Tendon Sheath 11/2021
1	Type 2 Diabetes Mellitus (MODY) 03/2013
1	Disease Progression 10/2012

Drug/Important Bio-Agent (IBA)

3	Ado-Trastuzumab EmtansineIBA 01/2019 - 12/2017
2	human ERBB2 proteinIBA 01/2019 - 12/2017
1	vedolizumabIBA 03/2024
1	pexidartinibIBA 11/2021
1	pertuzumabIBA 01/2019
1	ErbB Receptors (EGF Receptor)IBA 12/2017
1	Lapatinib (GW572016)FDA Link 12/2017
1	Trastuzumab (Herceptin)FDA Link 12/2017
1	taxaneIBA 12/2017
1	Capecitabine (Xeloda)FDA Link 12/2017
1	Sitagliptin Phosphate (Januvia)FDA Link 03/2013
1	LinagliptinIBA 03/2013
1	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 03/2013
1	Dipeptidyl-Peptidase IV InhibitorsIBA 03/2013
1	Apolipoprotein E4IBA 10/2012

Therapy/Procedure

1	Therapeutics 12/2017